Targeting BCL2-Proteins for the Treatment of Solid Tumours..pdf (718.89 kB)
Download file

Targeting BCL2-Proteins for the Treatment of Solid Tumours

Download (718.89 kB)
journal contribution
posted on 31.05.2016, 11:42 by Meike Vogler
Due to their central role in the regulation of apoptosis, the antiapoptotic BCL2-proteins are highly promising targets for the development of novel anticancer treatments. To this end, several strategies have been developed to inhibit BCL2, BCL-XL, BCL-w, and MCL1. While early clinical trials in haematological malignancies demonstrated exciting single-agent activity of BCL2-inhibitors, the response in solid tumours was limited, indicating that, in solid tumours, different strategies have to be developed in order to successfully treat patients with BCL2-inhibitors. In this review, the function of the different antiapoptotic BCL2-proteins and their role in solid tumours will be discussed. In addition, a comprehensive analysis of current small molecules targeting these antiapoptotic BCL2-proteins (e.g., ABT-737, ABT-263, ABT-199, TW-37, sabutoclax, obatoclax, and MIM1) will be provided including a discussion of the results of any clinical trials. This analysis will summarise the potential of BCL2-inhibitors for the treatment of solid tumours and will unravel novel approaches to utilise these inhibitors in clinical applications.

History

Citation

Advances in Medicine, 2014, 2014: 943648

Author affiliation

/Organisation/COLLEGE OF MEDICINE, BIOLOGICAL SCIENCES AND PSYCHOLOGY/MBSP Non-Medical Departments/Molecular & Cell Biology

Version

VoR (Version of Record)

Published in

Advances in Medicine

Publisher

Hindawi Publishing Corporation

issn

2356-6752

eissn

2314-758X

Copyright date

2014

Available date

31/05/2016

Publisher version

http://www.hindawi.com/journals/amed/2014/943648/

Language

en

Usage metrics

Categories

Keywords

Exports